Several pharmaceutical programs face setbacks impacting clinical and regulatory outlooks. Bristol Myers Squibb’s anemia drug Reblozyl failed its Phase 3 trial in myelofibrosis-associated anemia, missing its primary endpoint for transfusion independence despite showing some meaningful numerical benefits in secondary measures. GSK’s Blenrep received negative votes at FDA advisory panels due to safety and dosing concerns in multiple myeloma combinations. Viatris’ pimecrolimus ointment for eye inflammation failed late-stage trials, raising questions about the program’s future. These results underscore persistent hurdles in developing effective therapies for complex and underserved conditions.